8-K: Shattuck Labs Reports Strong 2025 Results, Advances SL-325

Shattuck Labs announced its full-year 2025 financial results, reporting reduced net losses and significant progress in its lead clinical program, SL-325.

Summary

• Net loss for the year ended December 31, 2025, decreased to $48.8 million, compared to $75.4 million for the year ended December 31, 2024.
• Research and Development (R&D) expenses for 2025 were $35.3 million, a significant decrease from $67.2 million in 2024, primarily due to the discontinuation of the SL-172154 program and related workforce reductions.
• General and Administrative (G&A) expenses for 2025 decreased to $17.2 million, from $19.1 million in 2024, mainly due to reduced compensation and legal fees.
• Cash and cash equivalents and short-term investments were approximately $78.1 million as of December 31, 2025, an increase from $73.0 million as of December 31, 2024.
• The Phase 1 clinical trial evaluating SL-325 in healthy volunteers is ongoing and progressing as planned, with full enrollment in the final multiple-ascending dose (MAD) cohort expected in the second quarter of 2026.
• Shattuck expects to disclose safety, tolerability, pharmacokinetics (PK), receptor occupancy, duration of receptor occupancy, and immunogenicity data from the SL-325 Phase 1 trial in the second quarter of 2026.
• Subject to positive Phase 1 data and regulatory alignment, Shattuck anticipates initiating a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in the third quarter of 2026.
• Shattuck's lead bispecific antibody has entered IND-enabling activities, with plans to disclose its targets, supporting preclinical data, and expected development timelines in the first half of 2026.
• In the first quarter of 2026, Shattuck sold shares of its common stock under its at-the-market offering facility for aggregate gross proceeds of $21.4 million.
• Current cash and cash equivalents and short-term investments, including the recent capital raise, are expected to fund operations into 2029.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, reflecting improved financial efficiency through reduced losses and R&D expenses, coupled with significant clinical progress for its lead asset, SL-325, and an extended cash runway.

Positives

• Net loss significantly decreased to $48.8 million in 2025 from $75.4 million in 2024, indicating improved financial performance.
• Research and Development expenses were nearly halved to $35.3 million in 2025 from $67.2 million in 2024, reflecting successful pipeline prioritization and cost management.
• General and Administrative expenses also decreased to $17.2 million in 2025 from $19.1 million in 2024.
• Cash and cash equivalents and short-term investments increased to $78.1 million as of December 31, 2025, from $73.0 million in 2024.
• The Phase 1 clinical trial for SL-325 is progressing as planned and is nearing completion, with data expected in Q2 2026.
• Shattuck anticipates initiating a Phase 2 clinical trial for SL-325 in Crohn's disease in Q3 2026, marking significant clinical advancement.
• The lead bispecific antibody has entered IND-enabling activities, expanding the company's pipeline with a novel approach.
• The company successfully raised $21.4 million through an at-the-market offering in Q1 2026, strengthening its financial position.
• Cash runway is projected to extend into 2029, providing long-term operational stability.
• Dr. Michael Choi, with extensive experience in inflammatory bowel disease programs, joined as Vice President of Clinical Development in November 2025.

Risks

• Global macroeconomic conditions and related volatility could impact operations.
• Expectations regarding the initiation, progress, and expected results of preclinical studies, clinical trials, and research and development programs may not be met.
• The unpredictable relationship between preclinical study results and clinical study results poses a risk to drug development.
• The timing or likelihood of regulatory filings and approvals for product candidates is uncertain.
• Liquidity and capital resources may not be sufficient to fund anticipated operations beyond the current guidance.
• Other risks and uncertainties identified in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

Shattuck expects to disclose Phase 1 SL-325 data in the second quarter of 2026 and initiate a Phase 2 trial in Crohn's disease in the third quarter of 2026, subject to positive data and regulatory alignment. The company also plans to disclose targets and development timelines for its lead bispecific antibody in the first half of 2026. Current capital resources, including recent capital raises, are projected to fund operations into 2029.

Management Comments

• "SL-325 is now the first DR3 blocking antibody to generate human clinical data, and we are very pleased with the progress we have made in our Phase 1 clinical trial, which is nearly complete."
• "We look forward to sharing the data from this trial in the second quarter, and anticipate initiating our Phase 2 clinical trial in Crohn's disease in the third quarter."

Industry Context

StockSavvy.ai notes that Shattuck Labs is positioning SL-325 as a potential first-in-class DR3 blocking antibody, targeting the DR3/TL1A pathway for inflammatory and immune-mediated diseases like Crohn's and ulcerative colitis. This pathway is a clinically validated target, and the company's focus on blocking DR3 rather than its ligand TL1A suggests a differentiated approach in a competitive therapeutic area for inflammatory bowel diseases. The advancement of a bispecific antibody further indicates a strategy to broaden its pipeline and potentially address multiple targets simultaneously for enhanced efficacy.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry.
• Shattuck highlights SL-325 as a 'potential first-in-class and best-in-mechanism DR3 blocking antibody' but does not offer detailed benchmarks against competitors' clinical trial outcomes or financial performance.

Management Changes

Related Party Transactions

• Related party license revenue was $0 for the year ended December 31, 2025.
• An investment in a related party of $1,000 thousand is listed on the balance sheet as of December 31, 2025.

Stakeholder Impact

• Shareholders: Potential positive impact due to reduced net losses, extended cash runway, and advancement of clinical pipeline, potentially increasing long-term value. Dilution from the at-the-market offering.
• Employees: Workforce reductions in 2024 impacted compensation and benefits, but the company is now advancing its lead programs.
• Patients: Potential future benefit from the development of SL-325 for inflammatory and immune-mediated diseases like Crohn's disease.
• Creditors: Improved financial stability with an extended cash runway.

Next Steps

• Complete full enrollment in the final multiple-ascending dose (MAD) cohort of the SL-325 Phase 1 trial in Q2 2026.
• Disclose safety, tolerability, PK, receptor occupancy, duration of receptor occupancy, and immunogenicity data from the SL-325 Phase 1 trial in Q2 2026.
• Initiate a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in Q3 2026, subject to positive Phase 1 data and regulatory alignment.
• Disclose targets, supporting preclinical data, and expected development timelines for the lead bispecific product candidate in H1 2026.
• Attend the Leerink Global Healthcare Conference 2026 from March 8-11, 2026.

Key Dates

Recommendation

Shattuck Labs shows promising clinical progress with SL-325 and has significantly improved its financial efficiency by reducing net losses and extending its cash runway into 2029. The advancement of its lead bispecific antibody also adds to the long-term potential. However, as a clinical-stage biotechnology company, significant risks remain, particularly regarding the outcome of ongoing and future clinical trials and regulatory approvals. The stock is a "hold" for investors awaiting further de-risking through positive Phase 1 data and successful initiation of Phase 2 trials, as well as more details on the bispecific program.

Keywords

Shattuck Labs, STTK, biotechnology, clinical-stage, DR3 blocking antibody, SL-325, Crohn's disease, inflammatory diseases, immune-mediated diseases, Phase 1 clinical trial, Phase 2 clinical trial, financial results, earnings, biopharma, drug development, at-the-market offering